Survival benefit of traditional chinese herbal medicine (a herbal formula for invigorating spleen) for patients with advanced gastric cancer

Integrative Cancer Therapies

Volumn 12, Issue 5, 2013, Pages 414-422

  Xu, Yan ^a   Zhao, Ai Guang ^a   Li, Zhao Yan ^a   Zhao, Gang ^b   Cai, Yong ^c   Zhu, Xiao Hong ^a   Cao, Ni Da ^a   Yang, Jin Kun ^a   Zheng, Jian ^a   Gu, Yin ^a   Han, Ying Ying ^a   Zhu, Ying Jie ^a   Yang, Jin Zu ^a   Gao, Feng ^a   Wang, Qiang ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Cox proportional hazard regression model; gastric cancer; overall survival; prospective study; traditional Chinese medicine

Indexed keywords

ANTHRACYCLINE; CISPLATIN; DOCETAXEL; FLUOROURACIL; OXALIPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CHINA; CHINESE MEDICINE; DEMOGRAPHY; FEMALE; FOLLOW UP; HERBAL MEDICINE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; STOMACH ADENOCARCINOMA; STOMACH CANCER; SURVIVAL TIME; TREATMENT DURATION;

COX PROPORTIONAL HAZARD REGRESSION MODEL; GASTRIC CANCER; OVERALL SURVIVAL; PROSPECTIVE STUDY; TRADITIONAL CHINESE MEDICINE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; MALE; MEDICINE, CHINESE TRADITIONAL; MIDDLE AGED; SPLEEN; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84883424576     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735412450512     Document Type: Article

References (19)

1. Kamangar F, Dores GM, Anderson WF.. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006 ; 24: 2137-2150 (Pubitemid 46655601)
2. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008 ; 358: 36-46
3. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006 ; 24: 4991-4997 (Pubitemid 46631401)
4. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008 ; 9: 215-221
5. Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008 ; 26: 1435-1442
6. Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008 ; 19: 1450-1457
7. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006 ; 24: 5201-5206 (Pubitemid 46631363)
8. Pinto C, Di Fabio F, Siena S, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol. 2007 ; 18: 510-517 (Pubitemid 46359631)
9. Han SW, Oh DY, Im SA, et al. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer. 2009 ; 100: 298-304
10. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 ; 376: 687-697
11. Zhao AG, Zhao HL, Jin XJ, Yang JK, Tang LD.. Effects of Chinese Jianpi herbs on cell apoptosis and related gene expression in human gastric cancer grafted onto nude mice. World J Gastroenterol. 2002 ; 8: 792-796
12. Zhao H, Zhao A, You S, et al. Growth-inhibiting and anti-metastasis effects of Weichang'an Decoction on orthotopic transplant nude mouse model of human gastric cancer [in Chinese]. Zhong Xi Yi Jie He Xue Bao. 2005 ; 3: 378-381
13. Zhao AG, Yang JK, You SF, et al. Effects of Chinese herbal recipe Weichang'an in inducing apoptosis and related gene expression in human gastric cancer grafted onto nude mice [in Chinese]. Zhong Xi Yi Jie He Xue Bao. 2007 ; 5: 287-297
14. Zhao AG, Li T, You SF, et al. Effects of Wei Chang An on expression of multiple genes in human gastric cancer grafted onto nude mice. World J Gastroenterol. 2008 ; 14: 693-700 (Pubitemid 351325050)
15. Food and Drug Administration. Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. Rockville, MD: Food and Drug Administration; 2007. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf. Accessed May 30, 2012.
16. Cao ND, Zhao AG, Yang JK.. Survival time of advanced gastric cancer patients treated with integrated traditional Chinese and Western medicine therapy [in Chinese]. Zhong Xi Yi Jie He Xue Bao. 2010 ; 8: 116-120
17. Zhao AG, Cao W, Xu Y, et al. Survival benefit of an herbal formula for invigorating spleen for elderly patients with gastric cancer [in Chinese]. Zhong Xi Yi Jie He Xue Bao. 2010 ; 8: 224-230
18. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001 ; 345: 725-730
19. Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011 ; 29: 3968-3976